ESR1 and breast cancer: Furthermore, we applied CRISPR-SelectTIME on human MCF7 breast cancer cells to confirm that the estrogen receptor ESR1-Y537S mutation, which is emerging as a major resistance mechanism in patients treated with the estrogen antagonist tamoxifen26,27, allows estrogen-independent proliferation/survival of MCF7 cells (Fig. 4d).